open access
Effect of mRNA COVID-19 vaccine on ovarian reserve of women of reproductive age
Affiliations- Department of Obstetrics and Gynecology, Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, Türkiye
- University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Türkiye, Türkiye
open access
Abstract
Objectives: To evaluate the effect of messenger ribonucleic acid (mRNA) vaccines developed for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) on the ovarian reserve of women of reproductive age.
Material and methods: This prospective study was conducted between July and December 2022 in a tertiary care hospital affiliated with a university. A total of 117 patients were included in the study. The patients were divided into two groups. The first group (n = 62) consisted of women of reproductive age who received two doses of Pfizer-BioNTech COVID-19 vaccine administered 21 days apart. The control group (n = 55) included women with the same demographic characteristics who did not plan to be vaccinated. Hormonal values and basal antral follicle count were compared between two groups.
Results: The mean age of the study group was 26.3 ± 3.6 years, and the mean age of the control group was 25.4 ± 6.2 years (p = 0.332). In the vaccinated group, mean follicular stimulating hormone (FSH) on day 2 was 5.29 ± 2.28; luteinizing hormone (LH): 5.18 ± 1.3; E2: 46.43 ± 24.51; anti-Mullerian hormone (AMH): 4.17 ± 2.1; antral follicle count: 16.23 ± 8.04; right ovarian volume: 6.4 ± 1.7; left ovarian volume: 6.2 ± 2.1. FSH measured at D2 in the control group was 5.68 ± 1.89; LH: 5.22 ± 2.2; E2: 48.41 ± 27.12; AMH: 4.30 ± 1.74; number of antral follicles: 15.64 ± 9.04; right ovarian volume: 6.1 ± 1.8; left ovarian volume: 6.3 ± 1.4. There were no statistically significant differences for FSH, LH, E2, AMH, ovarian volume, and number of antral follicles on the second day of menstruation between the groups.
Conclusions: According to the results of the present study, the mRNA SARS-CoV-2 vaccine does not affect the ovarian reserve of patients.
Abstract
Objectives: To evaluate the effect of messenger ribonucleic acid (mRNA) vaccines developed for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) on the ovarian reserve of women of reproductive age.
Material and methods: This prospective study was conducted between July and December 2022 in a tertiary care hospital affiliated with a university. A total of 117 patients were included in the study. The patients were divided into two groups. The first group (n = 62) consisted of women of reproductive age who received two doses of Pfizer-BioNTech COVID-19 vaccine administered 21 days apart. The control group (n = 55) included women with the same demographic characteristics who did not plan to be vaccinated. Hormonal values and basal antral follicle count were compared between two groups.
Results: The mean age of the study group was 26.3 ± 3.6 years, and the mean age of the control group was 25.4 ± 6.2 years (p = 0.332). In the vaccinated group, mean follicular stimulating hormone (FSH) on day 2 was 5.29 ± 2.28; luteinizing hormone (LH): 5.18 ± 1.3; E2: 46.43 ± 24.51; anti-Mullerian hormone (AMH): 4.17 ± 2.1; antral follicle count: 16.23 ± 8.04; right ovarian volume: 6.4 ± 1.7; left ovarian volume: 6.2 ± 2.1. FSH measured at D2 in the control group was 5.68 ± 1.89; LH: 5.22 ± 2.2; E2: 48.41 ± 27.12; AMH: 4.30 ± 1.74; number of antral follicles: 15.64 ± 9.04; right ovarian volume: 6.1 ± 1.8; left ovarian volume: 6.3 ± 1.4. There were no statistically significant differences for FSH, LH, E2, AMH, ovarian volume, and number of antral follicles on the second day of menstruation between the groups.
Conclusions: According to the results of the present study, the mRNA SARS-CoV-2 vaccine does not affect the ovarian reserve of patients.
Keywords
SARS-CoV-2 mRNA vaccine; AMH; ovarian reserve; COVID-19; fertility
About this articleTitle
Effect of mRNA COVID-19 vaccine on ovarian reserve of women of reproductive age
Journal
Issue
Article type
Research paper
Pages
200-205
Published online
2023-10-18
Page views
725
Article views/downloads
447
DOI
Pubmed
Bibliographic record
Ginekol Pol 2024;95(3):200-205.
Keywords
SARS-CoV-2 mRNA vaccine
AMH
ovarian reserve
COVID-19
fertility
Authors
Serkan Kumbasar
Suleyman Salman
Gizem Nur Çakmak
Fatma Ketenci Gencer
Leal Selin Sicakyüz
Ayşe Nur Kumbasar
References (29)- Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223): 470–473.
- Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
- Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020; 21(7): 2657.
- Jing Y, Run-Qian Li, Hao-Ran W, et al. Potential influence of COVID-19/ACE2 on the female reproductive system. Mol Hum Reprod. 2020; 26(6): 367–373.
- Sun J. The hypothesis that SARS-CoV-2 affects male reproductive ability by regulating autophagy. Med Hypotheses. 2020; 143: 110083.
- Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007; 212(1): 1–11.
- Kowalzik F, Schreiner D, Jensen C, et al. mRNA-based vaccines. Vaccines (Basel). 2021; 9(4): 390.
- Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601: 120586.
- Reis FM, Bouissou DR, Pereira VM, et al. Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 2011; 95(1): 176–181.
- Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007; 212(1): 1–11.
- Morris R, Morris A, IL N. Exposure of ovaries to COVID-19 vaccination does not impair fertility. Fertility and Sterility. 2021; 116(3): e473.
- Rameneni T, Sayeed T, Kumar S. A perspective on COVID-19 vaccine hesitancy in India. National Journal of Community Medicine. 2022; 13(07): 491–493.
- Lamptey E. Overcoming barriers to COVID-19 vaccination of pregnant women. Gynecology and Obstetrics Clinical Medicine. 2022; 2(1): 29–33.
- Buyalos RP, Daneshmand S, Brzechffa PR. Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy. Fertil Steril. 1997; 68(2): 272–277.
- Hsu A, Arny M, Knee AB, et al. Antral follicle count in clinical practice: analyzing clinical relevance. Fertil Steril. 2011; 95(2): 474–479.
- Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020; 105(11): 3361–3373.
- Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5): 305–306.
- Kis Z, Shattock R, Shah N, et al. Emerging technologies for low-cost, rapid vaccine manufacture. Biotechnol J. 2019; 14(1): e1800376.
- Anderson EJ, Rouphael NG, Widge AT, et al. mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; 383(25): 2427–2438.
- European Medicines Agency. Assessment Report EMA/707383/2020 Corr.1*: Comirnaty COVID-19 MRNA Vaccine (NucleosideModified); Assessment Report; European Medicines Agency: Volume 31, pp. 1–140 Amsterdam, The Netherlands, 2021.
- ‘European Medicines Agency. Assessment Report EMA/15689/2021 Corr.1*: Covid-19 Vaccine Moderna; European Medicines Agency: Volume 11, p. 169’. Amsterdam, The Netherlands, 2021.
- Bowman CJ, Bouressam M, Campion SN, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol. 2021; 103: 28–35.
- Li K, Chen Ge, Hou H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online. 2021; 42(1): 260–267.
- Mohr-Sasson A, Haas J, Abuhasira S, et al. The effect of Covid-19 mRNA vaccine on serum anti-Müllerian hormone levels. Hum Reprod. 2022; 37(3): 534–541.
- Soysal Ç, Yılmaz E. The effect of COVID-19 vaccine on ovarian reserve. Saudi Med J. 2022; 43(5): 486–490.
- Bentov Y, Beharier O, Moav-Zafrir A, et al. Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination. Hum Reprod. 2021; 36(9): 2506–2513.
- Horowitz E, Mizrachi Y, Ganer Herman H, et al. The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women. Reprod Biomed Online. 2022; 45(4): 779–784.
- Orvieto R, Noach-Hirsh M, Segev-Zahav A, et al. Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle? Reprod Biol Endocrinol. 2021; 19(1): 69.
- Odeh-Natour R, Shapira M, Estrada D, et al. Does mRNA SARS-CoV-2 vaccine in the follicular fluid impact follicle and oocyte performance in IVF treatments? Am J Reprod Immunol. 2022; 87(5): e13530.
